DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS  
DIRECTOR’S OFFICE  
PHARMACY – PROGRAM FOR UTILIZATION OF UNUSED PRESCRIPTION  
DRUGS  
(By authority conferred on the director of the department of licensing and regulatory affairs  
and board of pharmacy by sections 16145, 17701, and 17775 of the public health code, 1978 PA  
368, MCL 333.16145, 333.17701, and 333.17775 and Executive Reorganization Order Nos.  
1991-9, 1996-2, 2003-1, and 2011-4, MCL 338.3501, 445.2001, 445.2011, and 445.2030)  
R 338.3601 Definitions.  
Rule 1. (1) As used in these rules:  
(a) “Chemotherapeutic agent” means a chemical agent used for treating various forms of  
cancer generally by killing the cancer cells.  
(b) “Code” means the public health code, 1978 PA 368, MCL 333.1101 to 333.25211.  
(c) “Department” means the department of licensing and regulatory affairs.  
(d) "Eligible facility" means a medical institution as that term is defined in R 338.486.  
(e) “FDA” means the Federal Food and Drug Administration.  
(f) “Hazardous waste” means hazardous waste as that term is defined in R 299.9203.  
(g) “Original sealed and tamper-evident packaging” means unopened, tamper-evident  
packaging, as that term is defined in USP, Chapter 659, “Packaging and Storage Requirements,”  
including, but not limited to, an unopened unit-dose container or a multiple-dose container, as  
those terms are defined in USP, Chapter 659, “Packaging and Storage Requirements,” and  
immediate, secondary, and tertiary packaging.  
(h) "Program" means the statewide unused prescription drug repository and distribution  
program known as the program for utilization of unused prescription drugs that is established in  
section 17775 of the code, MCL 333.17775.  
(i) “Unit dose package” means a package that contains a single dose drug with the name,  
strength, control number, and expiration date of that drug on the label.  
(j) “Unit of issue package” means a package that provides multiple doses of the same drug,  
but each drug is individually separated and includes the name, lot number, and expiration date.  
(k) “USP” means the United States Pharmacopeia, published by the United States  
Pharmacopeial Convention.  
(l) “USP-NF” means the United States Pharmacopeia National Formulary.  
(m) “Waste disposal facility” means a waste diversion center or disposal facility that  
complies with the natural resources and environmental protection act, 1994 PA 451, MCL  
324.101 to 324.90106, for processing or disposal.  
(2) Terms defined in the code have the same meaning when used in these rules unless  
otherwise defined in these rules.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
Page 1  
R 338.3603.  
withdrawal.  
Eligibility criteria; pharmacy; charitable clinics; requirements;  
Rule 3. (1) To be eligible for participation in the program and to accept donated prescription  
drugs, a pharmacy or charitable clinic shall comply with all applicable federal and state laws,  
including laws applicable to the storage and distribution of drugs and the appropriate licensing  
standards, and shall hold an active, nonrestricted, license in this state.  
(2) Participation in the program is voluntary.  
(3) A pharmacy or charitable clinic may elect to participate in the program and accept  
donated prescription drugs by providing, on a form provided by the department, all the  
following:  
(a) The name, address, telephone number, and license number of the pharmacy and  
charitable clinic pharmacy licensed under article 15 of the code, MCL 333.16101 to 333.18838,  
or charitable clinic licensed under article 17 of the code, MCL 333.20101 to 333.22260.  
(b) For a charitable clinic, evidence that the charitable clinic meets the requirements in  
section 17775(2)(c) of the code, MCL 333.17775.  
(c) The name and license number of the responsible pharmacist employed by or under  
contract with the pharmacy or charitable clinic.  
(d) A statement signed and dated by the responsible pharmacist indicating that the  
pharmacy or charitable clinic meets the eligibility requirements under this rule and shall comply  
with the requirements of the program.  
(4) A participating pharmacy or charitable clinic may withdraw from participation in the  
program by providing written notice to the department on a form provided by the department. All  
of the following information must be included on the notice of withdrawal form:  
(a) Name, address, telephone number, and license number of the participating pharmacy or  
charitable clinic.  
(b) Name and dated signature of the responsible pharmacist, attesting that the participating  
pharmacy or charitable clinic shall no longer participate in the program.  
(c) Date of withdrawal.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3605 Eligible prescription drugs.  
Rule 5. (1) All non-controlled prescription drugs, except those specified in R 338.3607, that  
have been approved for medical use in the United States, are listed in the USP-NF, and meet the  
criteria for donation established by these rules may be accepted for donation under the program.  
(2) A new prescription may be transferred to another participating pharmacy or charitable  
clinic for dispensing.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3607 Ineligible drugs; controlled substances prohibited.  
Page 2  
Rule 7. (1) The following drugs must not be accepted for dispensing under the program:  
(a) Controlled substances, as described in R 338.3111.  
(b) Expired prescription drugs.  
(c) Drugs that may be dispensed only to a patient registered with the drug’s manufacturer  
under the FDA’s requirements.  
(d) Drugs that have been outside of a health professional’s control unless sanitation and  
security can be assured following inspection by a licensed pharmacist in accordance with R  
338.3609.  
(e) Compounded drugs.  
(f) Drugs that require storage temperatures other than normal room temperature as  
specified by the manufacturer or the USP-NF. This subdivision does not apply to drugs donated  
directly from a drug manufacturer or an eligible facility that has ensured the integrity of the drug  
by enclosing in the donation packaging a USP-recognized method by which the participating  
pharmacy or charitable clinic can easily detect improper temperature variations.  
(2) Controlled substances submitted for donation must be documented and returned  
immediately to the eligible facility that donated the drugs. Both of the following apply:  
(a) If controlled substances enter the participating pharmacy or charitable clinic and it is  
not possible or practicable to return the controlled substances to the donating facility, abandoned  
controlled substances must be documented and destroyed under the protocols currently used by  
the participating pharmacy.  
(b) A destruction record must be created and maintained for a period of 5 years after  
destruction of a controlled substance. Two years after the date of the destruction, the  
participating pharmacy or charitable clinic may make an electronic duplicate of the original  
record that becomes the original record of destruction. A participating pharmacy shall present a  
paper copy of the electronic duplicate to an authorized agent of the board on request.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3609 Standards and procedures for inspecting donated prescription drugs;  
participating pharmacy or charitable clinic requirements.  
Rule 9. (1) A participating pharmacy or charitable clinic may accept a prescription drug  
only if all of the following requirements are met:  
(a) The drug is in its original sealed and tamper-evident packaging. However, a drug in a  
single-unit dose, unit of issue package, or blister pack with the outside packaging opened may be  
accepted if the single-unit-dose packaging or unit of issue packaging is unopened.  
(b) The drug has been stored according to manufacturer or USP-NF storage requirements.  
(c) The packaging contains the expiration date of the drug and the lot number if the  
donation is received from an outsourcing facility. If the lot number is not retrievable, all  
specified medications must be destroyed if there is a recall.  
(d) The drug is not expired.  
(e) The drug does not have physical signs of tampering, adulteration, or misbranding and  
there is no reason to believe that the drug is adulterated or misbranded.  
(f) The packaging does not have physical signs of tampering, deterioration, compromised  
integrity, misbranding, or adulteration.  
Page 3  
(2) A participating pharmacy or charitable clinic may accept donated prescription drugs  
from more than 1 eligible facility if the prescription drugs are donated under the terms of the  
program.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3611 Donated prescription drugs; eligible facility, manufacturer requirements.  
Rule 11. (1) An eligible facility or manufacturer may donate unused or donated prescription  
drugs, other than controlled substances, to a participating pharmacy or charitable clinic if the  
drug meets the requirements of these rules.  
(2) A manufacturer or its representative may donate prescription drugs in complimentary  
starter doses, other than controlled substances, to a charitable clinic under the program if the  
drug meets the requirements of these rules.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3613 Rescinded.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3615 Transfer and shipment of donated drugs; requirements.  
Rule 15. (1) The eligible facility or manufacturer shall complete and transmit the eligible  
facility or manufacturer donation form or a substantively similar electronic or physical form in  
each shipment of donated prescription drugs to the participating pharmacy or charitable clinic.  
This form must comply with R 338.3621a.  
(2) Donated drugs under the program must be shipped from the eligible facility or  
manufacturer to the participating pharmacy or charitable clinic via common or contract carrier.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3617 Inspection and storage of donated prescription drugs; destruction; recall.  
Rule 17. (1) Before dispensing a donated drug, a licensed pharmacist, employed by or under  
contract with the participating pharmacy or charitable clinic, shall inspect donated prescription  
drugs to determine, in the professional judgment of the pharmacist, that the drugs are not  
adulterated or misbranded, are safe and suitable for dispensing, and are eligible drugs.  
(2) The participating pharmacy or charitable clinic shall store donated drugs under the  
manufacturer’s guidelines or USP-NF guidelines. Donated drugs must be stored and maintained  
in a manner that distinguishes them physically or electronically from other non-donated  
inventory.  
(3) If donated drugs are not inspected immediately upon receipt, a participating pharmacy or  
charitable clinic shall store the donated prescription drugs separately from all dispensing stock  
Page 4  
until the donated prescription drugs have been inspected and approved for dispensing under the  
program.  
(4) A participating pharmacy or charitable clinic shall destroy donated prescription drugs  
that are not suitable for dispensing under the protocols currently established by the pharmacy or  
charitable clinic for the destruction of prescription drugs. This includes unused prescription  
drugs that met eligibility requirements for distribution upon receipt but were subsequently not  
dispensed to an eligible patient under the program.  
(5) A participating pharmacy or charitable clinic shall create and maintain a destruction and  
disposal record for donated unused prescription drugs that are destroyed and disposed of as a  
result of being expired, adulterated, recalled, or otherwise not eligible for dispensing. A  
participating pharmacy or charitable clinic shall maintain a destruction record for 5 years after  
destruction of the donated drugs. Two years after the destruction of the donated drugs, the  
participating pharmacy or charitable clinic may make an electronic duplicate of the original  
record that becomes the original record. A participating pharmacy or charitable clinic shall  
present a paper copy of the electronic duplicate to an authorized agent of the board on request.  
(6) If a participating pharmacy or charitable clinic receives a recall notification, the  
participating pharmacy or charitable clinic shall perform a uniform destruction of all the recalled  
prescription drugs in the participating pharmacy or charitable clinic and complete the destruction  
record for all donated prescription drugs that are destroyed. The destruction must be done under  
the protocols currently established by the pharmacy or charitable clinic for the destruction and  
disposal of prescription drugs.  
(7) If a recalled drug has been dispensed, the participating pharmacy or charitable clinic  
shall immediately notify the eligible participant of the recalled drug under established drug recall  
procedures.  
(8) Notwithstanding any federal or state law, or rule to the contrary, a participating  
pharmacy may repackage a donated prescription drug or medical supply as necessary for storage,  
dispensing, administration, or transfers pursuant to both of the following:  
(a) Repackaged medicine must be labeled with the drug name, manufacturer, strength, and  
expiration date and must be stored in a separate designated area until inspected and initialed by a  
pharmacist.  
(b) If multiple packaged donated medicines with varied expiration dates are repackaged  
together, the shortest expiration date must be used.  
(c) The expiration date must be no later than 1 year after the date the drug was repackaged  
into a vial, no later than 6 months after repackaged into a compliance blister packaging, or no  
later than 60 days after repackaged into a customized patient medication package in accordance  
with R 338.525 that is prepared by a pharmacist for a specific patient and contains 2 or more  
prescribed solid oral dosage forms.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3619 Rescinded.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
Page 5  
R 338.3621 Forms; general requirements.  
Rule 21. (1) All forms required for participation in the program must be maintained  
separately from other records for 5 years except for prescriptions dispensed under the program  
which must be filed with the pharmacy’s other prescriptions. Two years after the record is made,  
the holder of the record may make an electronic duplicate of the original record that becomes the  
original record. The holder of the record shall present a paper copy of the electronic duplicate to  
an authorized agent of the board on request.  
(2) The department shall make available all forms required by the program. The forms must  
be available at no cost from the Department of Licensing and Regulatory Affairs, Bureau of  
Professional Licensing, 611 West Ottawa Street, Lansing, Michigan 48909 or on the  
also use a substantively similar electronic or physical form for all forms required by the program.  
(3) A participating pharmacy or charitable clinic shall maintain documented policies and  
procedures that address all the requirements of these rules.  
(4) A participating pharmacy or charitable clinic shall keep records as required under these  
rules and all applicable federal and state laws, rules, and regulations.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3621a  
requirements.  
Eligible facility donation form, manufacturer donation form;  
Rule 21a. An eligible facility or manufacturer donation form must include all of the  
following information:  
(a) The following information for the eligible facility or manufacturer that is donating  
prescription drugs:  
(i) The name, address, telephone number, and license number, if applicable.  
(ii) The name, dated signature, and license number of the pharmacist or healthcare provider  
authorized to make the donation, if applicable.  
(b) A statement of the eligible facility or manufacturer’s intent to participate in the program  
and donate to the participating pharmacy or charitable clinic identified on the form.  
(c) A statement that the unused medication is eligible for donation as defined by R  
338.3605 and R 338.3607.  
(d) The name, address, and telephone number of the participating pharmacy or charitable  
clinic that is receiving the donation.  
(e) The name, license number, and dated signature of the pharmacist authorized to receive  
the donation.  
(f) The date the donation was received by the participating pharmacy or charitable clinic.  
(g) An attestation that the transaction complies with the requirements of the drug supply  
chain security act, Public Law 113-54, or is subject to a waiver, exemption, or exception by the  
FDA.  
History: 2025 MR 11, Eff. May 7, 2025.  
Page 6  
R 338.3621b Eligible participant form; requirements.  
Rule 21b. The eligible participant form must include all of the following information before  
receiving the first donated prescription drug:  
(a) An attestation from the eligible participant that includes both of the following:  
(i) The eligible participant is a resident of this state.  
(ii) The eligible participant is eligible to receive medicare or medicaid or is uninsured and  
does not have prescription drug coverage.  
(b) The eligible participant acknowledges that the drug is donated.  
(c) The eligible participant consents to a waiver of the requirement for child resistant  
packaging, as required by the poison prevention packaging act of 1970, 15 USC 1471 to 1477.  
History: 2025 MR 11, Eff. May 7, 2025.  
R 338.3621c Transfer form; requirements.  
Rule 21c. A participating pharmacy or charitable clinic shall document on a transfer form  
all of the following for each donation made to the program:  
(a) The following information for each prescription drug:  
(i) Brand name or generic name of the drug.  
(ii) Name of the manufacturer and National Drug Code (NDC) Number.  
(iii) Quantity and strength of the drug.  
(iv) The container size.  
(v) The number of containers.  
(vi) The product identifier.  
(vii) Date the drug was donated.  
(viii) The date of the shipment, if more than 24 hours after the date of the transaction.  
(ix) Name of the eligible facility that donated the drug.  
(b) The name, address, telephone number, and license number of the participating  
pharmacy or charitable clinic receiving the donated prescription drug.  
(c) The name and license number of the responsible pharmacist authorized to receive the  
donated prescription drug.  
(d) An attestation stating that “I certify that the prescription drugs for donation are eligible  
for donation and meet the requirements for prescription drugs under the program, including  
storage requirements” made by the pharmacist or facility manager who is responsible or the  
eligible facility or manufacturer.  
(e) An attestation stating that this transaction complies with the requirements of the drug  
supply chain security act, Public Law 113-54, or is subject to a waiver, exemption, or exception  
by the FDA.  
History: 2025 MR 11, Eff. May 7, 2025.  
R 338.3621d Destruction form; requirements.  
Page 7  
R 21d. The destruction form must include all of the following:  
(a) The name, address, telephone number, and license number of the participating  
pharmacy or charitable clinic.  
(b) The name, license number, and dated signature of the responsible pharmacist.  
(c) The following information for each donated prescription drug that is destroyed:  
(i) The brand name or generic name of the drug.  
(ii) The name of manufacturer or NDC number.  
(iii) The quantity and strength of the drug.  
History: 2025 MR 11, Eff. May 7, 2025.  
R 338.3623 Rescinded.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3625 Dispensing donated prescription drugs; requirements.  
Rule 25. (1) A participating pharmacy or charitable clinic shall dispense a donated  
prescription drug in compliance with applicable federal and state laws and regulations for  
dispensing prescription drugs, including all requirements relating to packaging, labeling, record  
keeping, drug utilization review, and patient counseling.  
(2) The participating pharmacy or charitable clinic shall remove patient identifying  
information from the package before dispensing the drug.  
(3) A participating pharmacy or charitable clinic shall not resell a donated prescription drug;  
however, a participating pharmacy or charitable clinic may collect a handling fee under R  
338.3627.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3627 Handling fee.  
Rule 27. (1) A participating pharmacy or charitable clinic may charge the eligible  
participant receiving a donated prescription drug a handling fee, not to exceed the reasonable  
costs of participating in the program, including, but not limited to, the current and anticipated  
costs of educating eligible donors, providing technical support to participating donors, shipping  
and handling, labor, storage, licensing, utilities, advertising, technology, supplies, and  
equipment. A participating pharmacy or charitable clinic shall use reasonable efforts to ensure  
the handling fee does not exceed the total cost of obtaining the same drug outside the program.  
Nothing shall prevent the participating pharmacy or charitable clinic from accepting coverage of  
any applicable fees from another party when eligible participants may be unable to cover the  
cost.  
(2) A handling fee charged for a donated prescription drug dispensed through the program is  
not eligible for reimbursement under the medical assistance program.  
Page 8  
(3) The eligible participant shall not be charged a handling fee if the eligible participant is  
receiving a professional sample that is distributed to patients at the same charitable clinic who  
are ineligible for the program without a handling fee.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3629 Donation to other participating pharmacy or charitable clinic.  
Rule 29. A participating pharmacy or charitable clinic may donate prescription drugs that it  
has received under the program to other participating pharmacies or charitable clinics for use  
under the program. The participating pharmacy or charitable clinic donating the prescription  
drugs shall complete a transfer form required under R 338.3621c.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3631 Registry; creation.  
Rule 31. The department shall establish and maintain a participating pharmacy and  
charitable clinic registry for the program on the department’s website. The registry must include  
the name, address, and telephone number of the participating pharmacy or charitable clinic and  
the name of the responsible pharmacist.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3633 Collection of prescription drugs and other medication for destruction and  
disposal; requirements; limitations.  
Rule 33. (1) Under section 17776 of the code, MCL 333.17776, a participating pharmacy or  
charitable clinic shall accept from an individual a prescription drug or another medication that is  
ineligible for distribution under the program for destruction and disposal in accordance with 21  
CFR part 1317.  
(2) Unless allowed by federal law, controlled substances must not be collected by a  
participating pharmacy or charitable clinic for destruction and disposal.  
(3) If a participating pharmacy or charitable clinic accepts a chemotherapeutic agent for  
destruction, the chemotherapeutic agent must not be mixed with other prescription drugs  
collected for disposal under the program. The chemotherapeutic agent must be mixed with the  
participating pharmacy’s or charitable clinic’s hazardous waste.  
(4) A participating pharmacy or charitable clinic that collects prescription drugs and other  
medications for destruction and disposal shall collect the prescription drugs and medications on-  
site at the participating pharmacy or charitable clinic and shall follow these rules and all  
applicable state and federal laws and regulations.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3635 Collection device for ineligible drugs; requirements.  
Page 9  
Rule 35. A participating pharmacy or charitable clinic shall utilize a collection device to  
collect prescription drugs and other medications that, upon receipt, are ineligible for distribution  
under the program for destruction and disposal that meets all the following requirements:  
(a) Is designed to allow prescription drugs and other medications to be added to the device  
but allow only authorized personnel to remove the contents from the collection device for  
destruction and disposal.  
(b) Is securely fastened to a permanent structure.  
(c) Is a tamper resistant, securely locked, substantially constructed container with a  
permanent outer container and a removable inner liner.  
(d) Is labeled consistent with all applicable state and federal laws and regulations and  
includes the following statements prominently displayed on the collection device, and also in  
another location near the collection device:  
(i) “Controlled substances cannot be accepted for destruction and disposal, unless allowed  
under federal law.”  
(ii) “Chemotherapeutic agents must not be placed in this collection device.”  
(e) Is lined with a removable liner that is waterproof, tamper-evident, tear resistant, and  
capable of being sealed.  
(f) The contents of the collection device must not be viewable from the outside of the  
collection device and the size or capacity of the collection device must be clearly marked on the  
outside of the collection device.  
(g) Is monitored by security features and pharmacy personnel.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3637 Access to collection device; destruction of ineligible collected drugs.  
Rule 37. (1) For noncontrolled substances, the following rules of destruction must be  
followed:  
(a) An individual shall access a collection device utilizing a removable liner only for the  
following purposes:  
(i) To remove the contents for safe, effective, and immediate transportation.  
(ii) To immediately transfer the contents to a waste disposal facility.  
(iii) To immediately transfer the contents to a responsible individual for transportation to a  
waste disposal facility.  
(b) A collection device utilizing a removable liner must only be accessed as follows:  
(i) The access must be done by 2 personnel, 1 of whom is a licensed pharmacist,  
designated by the participating pharmacy or charitable clinic.  
(ii) Upon being accessed, the liner must be immediately sealed and the weight of the  
contents immediately recorded in the destruction and disposal log. A copy of the destruction log  
must be transferred with the sealed contents.  
(c) Within 1 year of collection, the contents of the collection device must be transferred to  
a waste disposal facility for destruction.  
(d) The contents of the collection device must be destroyed under all applicable state and  
federal laws and regulations.  
Page 10  
(2) For controlled substances, destruction procedures under federal law must be followed  
pursuant to 21 CFR 1317.95.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3639 Record keeping; policy and procedures; destruction and disposal log.  
Rule 39. (1) A participating pharmacy or charitable clinic shall maintain a destruction and  
disposal log that includes all the following information:  
(a) The name, telephone number, address, and license number of the participating  
pharmacy or charitable clinic.  
(b) The date, time, and weight of the contents of the collection device each time the  
contents of the collection device are removed for destruction.  
(c) The name, telephone number, and address of the individual who is responsible for  
transporting the contents to the waste disposal facility.  
(d) The name, telephone number, and address of the waste disposal facility where the  
contents of the collection device were transferred.  
(2) Copies of all contracts with transporters and waste disposal facilities must be stored with  
the destruction log, as applicable.  
(3) If controlled substances are destroyed, the participant must complete the Drug  
Enforcement Agency Form 41 and keep it for 2 years in accordance with 21 USC 827.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3641 Transportation.  
Rule 41. The contents of the collection device must be transferred to a waste disposal  
facility under all applicable state and federal laws and regulations.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
R 338.3643 Department of health and human services; inclusion in rulemaking process.  
Rule 43. The department shall notify the director of the department of health and human  
services of a request for rulemaking that is approved under section 39 of the administrative  
procedures act of 1969, 1969 PA 306, MCL 24.239, for any proposed rulemaking that would  
affect eligible facilities or mental health or substance abuse clients. The department of health  
and human services shall provide input regarding the proposed rulemaking to the department  
within 30 days after receipt of notification of the approved request for rulemaking.  
History: 2014 AACS; 2025 MR 11, Eff. May 7, 2025.  
Page 11  
;